Researchers analyzed data from more than 4,000 C. diff patients, 10.1 percent of whom developed a recurrent CDI.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Patients with community-onset healthcare associated C. diff, more than two hospitalizations two months prior to diagnosis, new gastric acid suppression, use of fluoroquinolone and other high-risk antibiotics at the beginning of the initial CDI as well as increased age predicted CDI recurrence.
Stays in an intensive care unit were associated with a lower risk of redeveloping a CDI.
Flagging patients at risk for recurring CDI could help improve treatment and prevention strategies, the researchers suggested in their abstract.
More Articles on Infection Control & Clinical Quality:
7 Findings on Healthcare Utilization Following Sepsis
Clinical Traditions Steadfast in Spite of Updated Evidence, Study Shows
50 Hospitals With the Lowest Serious Complication Rates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
